| Literature DB >> 35448280 |
Mahesh Padmalaya Bhat1,2, Venkatachalam Thendral1, Uluvangada Thammaiah Uthappa3, Kyeong-Hwan Lee2,4, Madhuprasad Kigga1, Tariq Altalhi5, Mahaveer D Kurkuri1, Krishna Kant6.
Abstract
CTCs (circulating tumor cells) are well-known for their use in clinical trials for tumor diagnosis. Capturing and isolating these CTCs from whole blood samples has enormous benefits in cancer diagnosis and treatment. In general, various approaches are being used to separate malignant cells, including immunomagnets, macroscale filters, centrifuges, dielectrophoresis, and immunological approaches. These procedures, on the other hand, are time-consuming and necessitate multiple high-level operational protocols. In addition, considering their low efficiency and throughput, the processes of capturing and isolating CTCs face tremendous challenges. Meanwhile, recent advances in microfluidic devices promise unprecedented advantages for capturing and isolating CTCs with greater efficiency, sensitivity, selectivity and accuracy. In this regard, this review article focuses primarily on the various fabrication methodologies involved in microfluidic devices and techniques specifically used to capture and isolate CTCs using various physical and biological methods as well as their conceptual ideas, advantages and disadvantages.Entities:
Keywords: biological method; cancer diagnostics; circulating tumor cells (CTCs); microfluidic device; physical method
Mesh:
Year: 2022 PMID: 35448280 PMCID: PMC9025399 DOI: 10.3390/bios12040220
Source DB: PubMed Journal: Biosensors (Basel) ISSN: 2079-6374
Figure 1Range of methods involved in physical and biological approaches for early-stage detection and isolation of CTCs.
Figure 2Microfluidic device designs fabricated using various techniques. (a) 3D-printed device showing the microchannels with layers and the filter holder; reprinted with permission from ref. [79], 2019, Royal Society of Chemistry. (b) Microfluidic device fabricated by photolithography showing spiral channel and cell trapping segments; reprinted with permission from ref. [89], 2018, Elsevier. (c) Representation of label-free enumeration of CTCs using a vortex chip connected to an impedance cytometry chip; reprinted with permission from ref. [95], 2019, John Wiley and Sons. (d) Schematic of the detection strategy of the micro-aperture chip system for CTC detection; reprinted with permission from ref. [96], 2015, Royal Society of Chemistry.
Figure 3Microfluidic device designs fabricated using various techniques. (a) Schematic of the working setup of the stretchable microfluidic device, with an inset showing the multi-flow microchannel with a real stretchable microfluidic device; reprinted with permission from ref. [102], 2021, Royal Society of Chemistry. (b) Schematic of hybrid microfluidic cell separation device showing CTC sorting by an inertial focusing microchannel followed by magnetic separation [107]. (c) Photomasks fabricated using offset printing showed better resolution and smooth surface over other laser printing techniques [108]. (d) Schematic illustration of the optically induced dielectrophoresis (ODEP) microfluidic system assembly where Layer A was composed of fabricated polydimethylsiloxane (PDMS) components; Layer B was composed of indium-tin-oxide (ITO) glass; Layer C was composed of double-sided adhesive tape with microfabricated microchannels; and Layer D was composed of ITO glass substrate coated with a layer of photoconductive material [85].
Figure 4Schematic illustration of microfluidic devices for the isolation of CTCs using various techniques. (a) An overview of a slanted weir device; separation of CTCs over a slanted weir based on distinct size and deformability [93]. (b) Schematic of the microfluidic device integrated with a PDMS microfiltration membrane for CTC capture; reprinted with permission from ref. [90], 2015, Elsevier. (c) Top view of the multi-flow effect of a size-dependent inertial migration microfluidic system representing rotation-induced lift force (FΩ) for the isolation of CTCs [62]. (d) Enrichment of CTCs using spiral microfluidic technology utilizing inertial lift force [120]. (e) Illustration chip, self-amplified inertial-focused cell bifurcation of CTCs in the microfluidic channel; reprinted with permission from ref. [121], 2020, American Chemical Society.
Figure 5Schematic illustration of microfluidic devices for the isolation of CTCs using various techniques. (a) Schematic of the working mechanism of a dual-antibody-functionalised microfluidic device for the isolation of CTCs using magnetic beads; reprinted with permission from ref. [143], 2018, American Chemical Society. (b) Schematics of label-free isolation of HeLa cells in ferrofluids under magnetic fields by magnetic buoyancy forces; reprinted with permission from ref. [144], 2015, Wlsevier. (c) Schematic of CTC isolation in bubble-based acoustic microstreaming, which releases smaller cells by trapping larger CTCs; reprinted with permission from ref. [103], 2020, Royal Society of Chemistry. (d) Schematic illustration of a multi-stage device consisting of a pair of IDTs and FIDTs to generate SSAWs and TSAWs for the isolation of CTCs; reprinted with permission from ref. [151], 2018, Elsevier.
Figure 6Schematic illustration of microfluidic devices for the isolation of CTCs using various techniques. (a) Schematic illustration of working principle of an inertial-ferrohydrodynamic cell separation chip in ferrofluids under a magnetic field; reprinted with permission from ref. [158], 2021, Royal Society of Chemistry. (b) Schematic of isolation of CTCs through filtration, followed by anti-CD45 antibody functionalized magnetic beads [115]. (c) Schematic illustration of e-chip exhibiting a conductive gold layer functionalised with EpCAM antibodies responsible for the capture and electrochemical release/lyse of CTCs; reprinted with permission from ref. [91], 2017, American Chemical Society. (d) Schematic of DLD working principle of AP-Octopus-Chip, where CTCs interact with micropillar-functionalised AuBO-SYL3C to get captured and released by Au-S bond disruption; reprinted with permission from ref. [161], 2019, John Wiley and Sons.
Figure 7Schematic illustration of microfluidic devices for the isolation of CTCs using various techniques. (a) GEM chip with eight parallel channels with an inlet and an outlet showing asymmetric herringbone grooves inside the channel; reprinted with permission from ref. [163], 2013, Royal Society of Chemistry. (b) Schematic of dual aptamer-functionalised PLGA nanofiber-based microfluidic chip for the isolation of various phenotypic CTCs; reprinted with permission from ref. [164], 2021, Royal Society of Chemistry. (c) Schematic of microchannel design with aptamer-modified micropillar array for capturing cancer cells and isolating their gDNA; reprinted with permission from ref. [106], 2018, American Chemical Society.
Figure 8Schematic illustration of microfluidic devices for the isolation of CTCs using various techniques. (a) Working strategy of SERS nano vectors for CTC capture, cell phe-notype profiling and multivariate analysis for in situ profiling of CTCs; reprinted with permission from ref. [166], 2018, John Wiley and Sons. (b) Schematic of the working setup of the microfluidic platform and surface modification of 3D-printed microfluidic device with an-ti-EpCAM antibody for the isolation of CTCs; reprinted with permission from ref. [81], 2020, Elsevier. (c) Schematic surface modification of 3D Ni foam scaffold with gelatin and anti-EpCAM to capture CTCs; these were released at 37 °C for molecular analysis; reprinted with permission from ref. [167], 2017, American Chemical Society. (d) Schematic of CTC isolation by a filtration chip functionalised with anti-EpCAM antibody and SEM image of captured cells on pyramidal MCA; reprinted with permission from ref. [170], 2019, Elsevier.
Overview of microfluidic devices with CTC isolation mechanism, chip fabrication and other technical parameters.
| Isolation Method | Device Fabrication | Device Dimension | Flow Rate | Efficiency | Cancer Cell Lines | Ref. |
|---|---|---|---|---|---|---|
|
| ||||||
| Size and deformability | Double-layer photolithography | L = 500 μm | 2.5 mL/h | ~97% | LM2 MDA-MB-231 | [ |
| Size | Wet etching technique and thermal bonding technique | L = 22 mm | 200 μL/min | 85% | BGC823, H1975, PC-3, SKBR3 | [ |
| Size-based PDMS microflitration membrane | Photolithography | T = 60 μm | 10 mL/h | >90% | A549, SK-MES-1, H446 | [ |
| Size | Photolithography | Main channel L = 80 µm; | 10 mL/h | 82% | SKBR3, MCF-7, MDAMB231 | [ |
|
| ||||||
| Label-free, inertial migration of cells | Photolithography | L = 20 mm | 300 µL/min | >99% | H460, HCC827 | [ |
| Rotation-induced inertial lift force | photolithography | W = 100, 200, 400 µm | 9 µL/min | 90% | U87 | [ |
| Dean vortex flow, inertial lift force | Photolithography | - | 1.7 mL/min | 54% | FaDu, CAL27, RPMI2650, UD-SCC9 HNC cells, MDA-MB-468 | [ |
| Inertial and Dean drag forces | Photolithography | W = 500 μm | 100 μL/min | ≥85% | MDA-MB-231, MCF-7, T24 | [ |
| Inertial microfluidics and Dean flow physics | Photolithography | L = 9.75 mm | 400–2700 μL/min | >94% | MDA-MB-231, Jurkat, K562, HeLa | [ |
| Size-dependent lateral migration | Photolithography | Capillary inner and outer diameter = 50 and 360 μm; | 200 μL/min | 94% | MCF-7 | [ |
| Self-amplified inertial-focused (SAIF) separation | Photolithography | Zigzag channel W = 40 μm; | 0.4 mL/min | ~80% | A549, MCF-7, HeLa | [ |
| Vortex and inertial cell focusing lift force | Photolithography | L = 1000 μm | 8 mL/min | 83% | MCF-7 | [ |
| Inertial lift force and Dean drag force | Photolithography | L = 5.5 mm | 1 mL/min | 90% | MCTC | [ |
|
| ||||||
| Optically induced dielectrophoretic (ODEP) force | Metal mould-punching | Main channel, L = 25 mm, W = 1000 μm, H = 100 μm; | 2.5 μL/min | 41.5% | PC-3 | [ |
| Dielectrophoresis at wireless bipolar electrode (BPE) array | Photolithography | L = 2.95 mm | 20 μm/s | 96% | MDA-MB-231, Jurkat E6-1 T | [ |
| Dielectrophoresis (DEP) force | Photolithography and wet etching | L = 7 mm | 100 µL/min | 92 ± 9% | NCI-H1975 | [ |
| Optically induced dielectrophoresis (ODEP) | Metal mould-punching | Main channel, L = 2500 µm, W = 1000 μm, H = 60 μm; Side channel, L = 2500 μm, W = 400 μm, H = 60 μm | - | 81.0 ± 0.7% | PC-3, SW620 | [ |
|
| ||||||
| Immunomagnetics and size-based filtration | Photolithography | T = 50 μm | 2 mL/min | ~89% | MCF-7 | [ |
| EpCAM-specific conjugation of MNPs | Photolithography | Microchannel W = 250 μm; | 150 µL/min | ~81.2–96.3% | MDA-MB-231, MCF-7 | [ |
| EpCAM-based positive method and CD45/CD66b-based negative method by lateral magnetophoresis | Photolithography | Free-bead capture microchannel, L = 42.5 mm, W = 1 mm, H = 50 µm; | 2 mL/h and 3.2 mL/h | 83.1% | MDA-MB-231, PC-3, SKBR3, MCF-7 | [ |
| Magnet deformability | Photolithography | L = 49,000 µm | 3 mL/h | 90% | HCT116, SW480, MCF-7 | [ |
| Immunomagnetic technique | Photolithography | L = 9 mm | - | 97–107% | SKBR3, PC-3, Colo205 | [ |
| Magnetic-ranking cytometry and phenotypic profiling of CTCs | Photolithography | L = 8.75 cm | 500 µL/h | >90% | SKBR3, PC-3, MDA-MB-231 | [ |
| MNP-labeled aptamers | Photolithography | - | 25 mL/h | ~79% | PC-3, SKBR3 | [ |
| Magnetic-bead-mediated dual-antibody functionalised microfluidics | Photolithography | - | 0.8 mL/h | >85% | LnCAP and LnCAP-EMP | [ |
| Cell size difference in ferrofluids under permanent magnetic influence | Photolithography | L = 2.54 mm | 8 µL/min | >99% | HeLa | [ |
| Ferrodynamic cell separation | Photolithography | L = 4.94 cm | 6 mL/h | ~92.9% | H1299, A549, H3122, PC-3, MCF-7, HCC1806 | [ |
|
| ||||||
| Cell size difference in ferrofluids | Photolithography | L = 5.81 cm | 20 µL/min | 82.2% | A549, H1299, MCF-7, MDA-MB-231 | [ |
| Lateral cavity acoustic transducers | Photolithography | W = 750 µm | 25 µL/min | 94% | Breast, bone, lung cancer cells | [ |
| Hydrodynamic and SAW focusing separation | Photolithography | - | 7.5 mL/h | >86% | MCF-7, HeLa, PC-3, LNCaP | [ |
| Interdigital transducers (IDTs) and focused interdigital transducers (FIDTs) generating standing SAWs and travelling pulsed SAWs | Photolithography | W = 65 µm | 0.3 µL/min | ~90% | U87 | [ |
| Acoustic impedance contrast | Photolithography and deep reactive ion etching (DRIE) | L = 20 mm | 20–60 µL/min | >86% | HeLa, MDA-MA-231 | [ |
| Microvortices generated by acoustic vibration | Photolithography | L = 50 mm | 10 µL/min | >90% | DU145 | [ |
| Continuous flow acoustophoretic negative selection | Photolithography | Maun channel, L = 20 mm, W = 375 µm, H = 150 µm; | 100, 400 µL/min | >98% | MCF-7, DU145 | [ |
|
| ||||||
| Inertial and magnetic method | Photolithography | W = 400 µm | 1000 µL/min | ~95% | MCF-7 | [ |
| Vortex trapping and impedance cytometry | - | L = 1 cm | 100 µL/min | ~ 98% | MCF-7, LoVo, HT-29 human colon cells, | [ |
| Inertial hydrodynamic forces and bifurcation law | CNC micromachining | W = 0.26 mm | - | 85% | MCF-7 | [ |
| Inertial and deformability-based principle | Photolithography | L = 1–1.5 cm | 80 mL/h | >90% | MCF-7 | [ |
| Integrated device with acoustofluidic label-free separation and direct dielectrophoretic cell trapping | Photolithography | L = 2.3 cm | 80, 160 µL/min | ~76% | DU145 | [ |
| Inertial-ferrohydrodynamic cell separation | Photolithography | H = 60 µm | ~60 mL/h | 94.8% | H1299, MDA-MB-231, MCF-7, H3122 | [ |
| Micropore-arrayed filtration and magnetic bead-functionalised antibody-mediated detection | Molding technique | Micropore L, W = 20 mm, diameter = 10 µm | - | ~85% | PC-9 | [ |
| Lateral cavity acoustic transducers (LCAT) and biomarker-based immuno-labelling | Photolithography | Main, side channel W = 500, 100 µm | 25 µL/min | ~100% | MCF-7, SKBR3 | [ |
|
| ||||||
| Antibody-mediated electrochemical release and lysis | Photolithography | L = 40 mm | 1 mL/h | 85–100% | PC-3, MCF-7, NCl-H1650 | [ |
| Electrochemical detection and electric-filed influenced hydrodynamic flow | Screen printing | W = 95 ± 2.5 µm | 5 µL/min | 92 ± 0.5% | HEK-293, HeLa | [ |
|
| ||||||
| EpCAM-expressing cells using antibody-coated microposts | Photolithography | L = 20 mm | 1.5–2.5 mL/h | 93% | PC-3 | [ |
| Aptamer-functionalized micropillars | Photolithography | - | 1 mL/h | 80% | W480 colorectal, LNCap prostate, KATO III gastric cancer cells, K-562 chronic myelogenous leukemia cells | [ |
| Anti-EpCAM-coated channel surface with herringbone grooves | Photolithography | L = 50 mm | 1 µL/s | >90% | L3.6pl, BxPC-3, MIAPaCa-2 | [ |
| EpCAM antibody-functionalised pillars | Laser direct-write technique | Micropost diameter = 420 µm; | 90 µL/min | ~76% | HEC-1A | [ |
| Combination of anti-EpCAM antibody and anti-N-cadherin antibody | Photolithography | L = 32 mm | 0.6 mL/h | 89.6% | SKOV-3 ovarian tumor cells | [ |
| Dual aptamer (EpCAM-5-1 and NC3S)-modified poly(lactic-co-glycolic acid) (PLGA) nanofiber | Electrospinning | L = 2 cm | 300 µL/min | 89–91% | A2780, OVCAR-3 | [ |
| Aptamer-immobilized microchannel | Photolithography | Cell channel W = 1 mm; | 5 µL/min | - | HeLa, CAOV-3 | [ |
| AlGaN/GaN HEMT biosensor array | Photolithography | L = 22 mm | - | - | HCT-8 | [ |
| Size-based and multiplex SERS nanovectors | - | Filter gap = 12 µm, | 1 µL/min | ~87–93% | SKBR3, MCF7, and MDA-MB-231 | [ |
| Microchannel functionalised with anti-EpCAM | 3D printing | L = 2 cm | 1 mL/h | ~87–92% | MCF-7, SW480, PC-3, 293T | [ |
| Gelatin-coated Ni foam functionalised with anti-WpCAM | Ni foam surface modification | L = 20 mm | 50 µL/min | ~88% | MCF-7 | [ |
| Lateral displacement (DLD) and herringbone CTC chip functionalised with EpCAM and CD41 antibodies | Deep reactive ion etching | H = 150 µm | 1.14 ± 0.24 mL/h | 60–83% | Lung, breast, melanoma cancer cells | [ |
| EpCAM and CD133 antibodies functionalised hexagonal array of posts | Photolithography | L = 44.6 mm | 1 mL/h | 13.6–97.5% | HT-29, Panc-1, PC-3, Hs-578T, Capan-1 | [ |
| Microcavity array functionalised with anti-EpCAM | Photolithography | H = 200 ± 10 µm | 0.1 mL/min | ~76–83% | MCF-7, SW620 | [ |
| Magnetic ranking cytometry and CTC surface marker expression | Photolithography | L = 5.4 cm | 400 µL/h | >90% | LNCaP, PC-3, PC-3M | [ |
| Isolation by size of epithelial tumor cell (ISET) and microbeads assisting ISET | - | L = 4 mm | 1 mL/min | ~72–93% | MCF-7, KATO III, PC-3 | [ |